Trials / Withdrawn
WithdrawnNCT01167335
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
A 12-week, Randomized, Double-blind, Placebo-controlled Exploratory Study to Assess the Antiepileptic Activity of BGG492 Given Orally as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy of BGG492 as adjunctive treatment in patients with refractory partial onset seizures
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGG492 | |
| DRUG | Placebo |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2010-11-01
- First posted
- 2010-07-22
- Last updated
- 2012-05-01
Locations
23 sites across 11 countries: United States, Austria, Belgium, Bulgaria, Canada, Estonia, India, Latvia, Lithuania, Romania, Spain
Source: ClinicalTrials.gov record NCT01167335. Inclusion in this directory is not an endorsement.